BOULDER, Colo.–(BUSINESS WIRE)—- $CLVS–Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment achieved the primary endpoint of significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR) compared with the control group, which consisted of physician’s choice of docetaxel, abiraterone acetate, or enzalutamide. Benefit wa
Click here to view original post
News
STAT+: Cambridge announced as ‘investor catalyst’ hub for ARPA-H
Cambridge has been chosen as one of three national hubs for a new federal health research agency that plans to spend billions to accelerate breakthroughs to vanquish diseases like cancers and Alzheimer’s. The Advanced Research […]
News
New Filtered Far UV-C Handheld Device Surface Reflectivity Study
DETROIT–(BUSINESS WIRE)–Freestyle Partners, LLC, announced today that a surface reflectivity study demonstrated that a filtered Far UV-C portable, handheld device when used as intended does not generate harmful amounts of reflected UV-C light to the […]
News
Ocutrx Unveils 3D Breakthrough, Enhancing Spine Surgery with Ergonomically Designed DigiLoupes Technology
Spinal Surgery Expert Dr. Leonel Hunt, M.D. Joins the Ocutrx Medical Advisory Board, Providing Scientific Guidance for Ocutrx’s Digital Loupe Innovations IRVINE, Calif. and COLORADO SPRINGS, Colo., Jan. 24, 2024 /PRNewswire/ — Ocutrx Technologies, Inc., […]
